Home | Welcome to Contract Pharma   
Last Updated Saturday, May 30 2015


Financial Report: Lonza

By Kristin Brooks

Published January 23, 2014

FY Revenues: CHF 3.6 billion  (-4%)

FY Earnings: CHR 87 million (-44%)

Comments: Pharma & Biotech sales, which include Lonza’s custom manufacturing and Bioscience sectors, were down 8% to CHF 1.4 billion. Revenues were impacted by product portfolio optimizations and the initiation of several major projects. The first quarter saw a scheduled production stop for the build-out at the company’s ADC plant in Visp. Its large-scale mammalian cell culture facility in Singapore implemented multiple plant adaptations, and the company began the phasedown of the Hopkinton, MA microbial biologics plant, which incurred restructuring costs of CHF 46 million. Specialty Ingredients sales were CHF 2.2 billion, down 1%.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On